Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

26 Sep Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

– Enrollment completed within planned timeframe of 14 months –

– IGV-001 granted Fast Track designation by U.S. FDA –

– $35 million financing completed in 2024 to fund operations beyond expected Phase 2b data readout in mid-2025 –

PHILADELPHIA, May 21, 2024–(BUSINESS WIRE)–Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire™ immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad and durable immune response against tumors. The primary endpoint of the Phase 2b trial is Progression Free Survival (PFS) and top-line data is expected by mid-2025.

Read the full article here